This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APRI Apricus Biosciences (APRI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Apricus Biosciences Stock (NASDAQ:APRI) 30 days 90 days 365 days Advanced Chart Get Apricus Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2 shsAverage Volume558,386 shsMarket Capitalization$14,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSeelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.Read More… Receive APRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apricus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address APRI Stock News HeadlinesEnlyte Launches Apricus Physical Medicine, Offering End-to-End Specialty Service Solution for IndustryOctober 10, 2024 | tmcnet.comApricus Generation Acquires Solar and Storage Developer Nexus RenewablesMay 29, 2024 | tmcnet.comTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionApril 26, 2025 | Crypto 101 Media (Ad)Lundquist Institute Start-Up Vitalex Biosciences Awarded Grant from NIAID/NIHMay 16, 2023 | finance.yahoo.comErectile Dysfunction Market Analysis and Growth Foresights till 2031May 16, 2023 | marketwatch.comErectile Dysfunction Drugs Market Market Projection and Growth Drivers 2023-2028April 29, 2023 | marketwatch.comErectile Dysfunction Drugs Market 2023-2028 Recent Study by Trend and Growth AnalysisMarch 11, 2023 | marketwatch.comErectile Dysfunction Medicine Market : Key Player, Competition Weakness and Strengths from 2023 to 2028January 10, 2023 | marketwatch.comSee More Headlines APRI Stock Analysis - Frequently Asked Questions How were Apricus Biosciences' earnings last quarter? Apricus Biosciences, Inc. (NASDAQ:APRI) announced its earnings results on Wednesday, October, 31st. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. What other stocks do shareholders of Apricus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apricus Biosciences investors own include Scotts Miracle-Gro (SMG), Pfizer (PFE), Just Eat Takeaway.com (GRUB), Boston Beer (SAM), Amicus Therapeutics (FOLD), Palatin Technologies (PTN) and Synergy Pharmaceuticals (SGYP). Company Calendar Last Earnings10/31/2018Today4/26/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:APRI CIK1017491 Webwww.apricusbio.com Phone(646) 293-2100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-216.45% Return on Assets-153.13% Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio3.86 Sales & Book Value Annual Sales$5.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / BookN/AMiscellaneous Outstanding Shares28,170,000Free FloatN/AMarket Cap$14,000.00 OptionableNot Optionable Beta1.20 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:APRI) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apricus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apricus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.